You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 149 No. 12, December 1989 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL INVESTIGATIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Polyvalent Immune Globulin and Cytomegalovirus Infection After Renal Transplantation

Bertram L. Kasiske, MD; Karen L. Heim-Duthoy, PharmD; Kathryn L. Tortorice, PharmD; Arthur L. Ney, MD; Mark D. Odland, MD; K. Venkateswara Rao, MD

Arch Intern Med. 1989;149(12):2733-2736.


Abstract

• To determine whether polyvalent, immune globulin (IgG) prevents cytomegalovirus (CMV) infection after cadaver renal transplantation, 28 patients were randomly allocated to receive 12 weekly infusions of 500 mg/kg of IgG (n = 15) or no treatment (n = 13). Both groups were similar with respect to age, sex, antigen mismatches, number of diabetics, and pretransplant donor/recipient CMV antibody titers. Moderately severe CMV infections occurred in 10 (77%) of 13 control subjects compared with 8 (53%) of 15 IgG-treated patients (not significant). Among those who developed CMV infections, prophylactic IgG had no effect on the severity or duration of fever, leukopenia, or hepatic enzyme elevations. Since none of the IgG-treated patients or control subjects in this study developed life-threatening CMV complications, a beneficial effect of prophylactic IgG in the small number of patients at risk for more severe CMV infections could not be excluded. However, this investigation suggests that the routine, prophylactic administration of polyvalent IgG, to prevent or to ameliorate CMV infection in unselected cadaver renal transplant recipients, is not warranted.

(Arch Intern Med. 1989;149:2733-2736)



Author Affiliations

From the Departments of Medicine, Hennepin County Medical Center, University of Minnesota Medical School, Minneapolis.


Footnotes

Accepted for publication June 19, 1989.

Presented in part at the 21st annual meeting of the American Society of Nephrology, San Antonio, Tex, December 11-14, 1988.

Reprint requests to Department of Medicine, Hennepin County Medical Center, 701 Park Ave, Minneapolis, MN 55415 (Dr Kasiske).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Management of herpes virus infections following transplantation
J Antimicrob Chemother 2000;45:729-748.
FULL TEXT  

New Strategies for Prevention and Therapy of Cytomegalovirus Infection and Disease in Solid-Organ Transplant Recipients
Sia and Patel
Clin. Microbiol. Rev. 2000;13:83-121.
ABSTRACT | FULL TEXT  

Statistical Power and Polyvalent Immunoglobulin
Whittle
Arch Intern Med 1990;150:1760-1760.
ABSTRACT  

Statistical Power and Polyvalent Immunoglobulin
Kasiske
Arch Intern Med 1990;150:1760-1760.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1989 American Medical Association. All Rights Reserved.